Catalog No.: PC-20690Not For Human Use, Lab Use Only.
Ebselen (CCG-39161, PI-1005) is a potent voltage-dependent calcium channel (VDCC) blocker, also potently inhibits SARS CoV-2 Mpro with IC50 of 0.67 μM.
Ebselen (CCG-39161, PI-1005) is a potent voltage-dependent calcium channel (VDCC) blocker, also potently inhibits SARS CoV-2 Mpro with IC50 of 0.67 μM. Ebsele covalently binds to C145 of the catalytic SARS CoV-2 Mpro, shows strong antiviral effects at a concentration of 10 μM in COVID-19 virus infected Vero cells. Ebselen inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic, renal cancer cell lines. Ebselen also is a first-in-class inhibitor of the YTHDF m6A-binding domain, engages YTHDF proteins within cells, interfering with their mRNA binding.
Physicochemical Properties
M.Wt
274.18
Formula
C13H9NOSe
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
2-phenylbenzo[d][1,2]selenazol-3(2H)-one
References
1. Liang Q, et al.et al. Front Neurosci. 2019 Oct 14;13:1073.
2. Micaelli M, et al. ACS Pharmacol Transl Sci. 2022 Sep 14;5(10):872-891.
3. Jin Z, et al. et al. Nature. 2020 Apr 9.
4. Hanavan PD, et al. Oncotarget. 2015 Jul 30;6(21):18418-28.
